Ana Elena Aviña

Dr. Ana Elena Aviña

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Nguyen Le Thanh HangNguyen Le Thanh Hang
Nguyen Le Thanh Hang
AAAna Elena Aviña
Ana Elena Aviña
CCCheng-Jen Chang
Cheng-Jen Chang
TYTzu-Sen Yang
Tzu-Sen Yang
Articular cartilage is an avascular and aneural connective tissue that is frequently damaged due to trauma or degenerative joint diseases, often resulting in arthritis. Its limited intrinsic capacity for self-renewal poses a significant challenge to effective repair. Hence, the development of regenerative strategies is essential to enhance the poor intrinsic healing of cartilage tissue. Photobiomodulation (PBM) has gained increasing attention as a noninvasive, drug-free, and safe approach. PBM exerts photobiological effects that promote cellular responses and reduce inflammatory conditions, all of which are beneficial for cartilage repair. Nonetheless, the efficacy of PBM varies depending on treatment parameters and treated targets. This review first summarizes PBM parameter-dependent outcomes in cartilage regeneration studies. Reported data indicate frequent use of red lasers (600–660 nm, 0–10 J/cm2), GaAIAs lasers (800–880 nm, 10–50 J/cm2), and Nd:YAG lasers (1064 nm, up to 200 J/cm2) in in vitro, in vivo, and clinical studies. Moreover, PBM in conjunction with cartilage tissue engineering (CTE) has shown synergistic effects, enhancing scaffold-based repair outcomes. This review additionally explores PBM applications within CTE frameworks. The summarized findings aim to inform researchers and physicians by outlining optimized PBM strategies and highlighting PBM’s strong potential in promoting cartilage regeneration, both independently and in combination with CTE.

3 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AWAline Yen Ling Wang
Aline Yen Ling Wang
KCKuan-Hung Chen
Kuan-Hung Chen
HLHsiu-Chao Lin
Hsiu-Chao Lin
CLCharles Yuen Yung Loh
Charles Yuen Yung Loh
YCYunching Chang
Yunching Chang
FWFu-Chan Wei
Fu-Chan Wei
Vascularized composite allotransplantation is an emerging strategy for the reconstruction of unique defects such as amputated limbs that cannot be repaired with autologous tissues. In order to ensure the function of transplanted limbs, the functional recovery of the anastomosed peripheral nerves must be confirmed. The immunosuppressive drug, tacrolimus, has been reported to promote nerve recovery in animal models. However, its repeated dosing comes with risks of systemic malignancies and opportunistic infections. Therefore, drug delivery approaches for locally sustained release can be designed to overcome this issue and reduce systemic complications. We developed a mixed thermosensitive hydrogel (poloxamer (PLX)-poly(l-alanine-lysine with Pluronic F-127) for the time-dependent sustained release of tacrolimus in our previous study. In this study, we demonstrated that the hydrogel drug degraded in a sustained manner and locally released tacrolimus in mice over one month without affecting the systemic immunity. The hydrogel drug significantly improved the functional recovery of injured sciatic nerves as assessed using five-toe spread and video gait analysis. Neuroregeneration was validated in hydrogel–drug-treated mice using axonal analysis. The hydrogel drug did not cause adverse effects in the mouse model during long-term follow-up. The local injection of encapsulated-tacrolimus mixed thermosensitive hydrogel accelerated peripheral nerve recovery without systemic adverse effects.

4 February 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
AWAline Yen Ling Wang
Aline Yen Ling Wang
AAAna Elena Aviña
Ana Elena Aviña
YLYen-Yu Liu
Yen-Yu Liu
YCYunching Chang
Yunching Chang
HKHuang-Kai Kao
Huang-Kai Kao
B-lymphocyte-induced maturation protein 1 (Blimp-1) is a transcription factor that, among other functions, modulates metabolism and helps to regulate antioxidant pathways, which is important in the context of chronic inflammatory diseases like diabetes, cardiovascular disease, and autoimmune disease. In immune cell function, Blimp-1 has a modulatory role in the orchestration of metabolic reprogramming and as a promoter of anti-inflammatory cytokines, including IL-10, responsible for modulating oxidative stress and immune homeostasis. Moreover, Blimp-1 also modulates key metabolic aspects, such as glycolysis and fatty acid oxidation, which regulate reactive oxygen species levels, as well as tissue protection. This review depicts Blimp-1 as an important regulator of antioxidant defenses and anti-inflammation and suggests that the protein could serve as a therapeutic target in chronic inflammatory and metabolic dysregulation conditions. The modulation of Blimp-1 in diseases such as diabetic coronary heart disease and atherosclerosis could alleviate oxidative stress, augment the protection of tissues, and improve disease outcomes. The therapeutic potential for the development of new treatments for these chronic conditions lies in the synergy between the regulation of Blimp-1 and antioxidant therapies, which are future directions that may be pursued. This review emphasizes Blimp-1’s emerging importance as a novel regulator in the pathogenesis of inflammatory diseases, providing new opportunities for therapeutic intervention.

Verified
Journal Article
Open access
PDF file
DPDante De Paz
Dante De Paz
AAAna Elena Aviña
Ana Elena Aviña
ECEsteban Cardona
Esteban Cardona
CLChin-Ming Lee
Chin-Ming Lee
CLChia-Hsien Lin
Chia-Hsien Lin
AWAline Yen Ling Wang
Aline Yen Ling Wang
Vascularized composite allografts contain various tissue components and possess relative antigenicity, eliciting different degrees of alloimmune responses. To investigate the strategies for achieving facial allograft tolerance, we established a mouse hemiface transplant model, including the skin, muscle, mandible, mucosa, and vessels. However, the immunomodulatory effects of the mandible on facial allografts remain unclear. To understand the effects of the mandible on facial allograft survival, we compared the diversities of different facial allograft-elicited alloimmunity between a facial osteomyocutaneous allograft (OMC), including skin, muscle, oral mucosa, and vessels, and especially the mandible, and a myocutaneous allograft (MC) including the skin, muscle, oral mucosa, and vessels, but not the mandible. The different facial allografts of a BALB/c donor were transplanted into a heterotopic neck defect on fully major histocompatibility complex-mismatched C57BL/6 mice. The allogeneic OMC (Allo-OMC) group exhibited significant prolongation of facial allograft survival compared to the allogeneic MC group, both in the presence and absence of FK506 immunosuppressive drugs. With the use of FK506 monotherapy (2 mg/kg) for 21 days, the allo-OMC group, including the mandible, showed prolongation of facial allograft survival of up to 65 days, whereas the myocutaneous allograft, without the mandible, only survived for 34 days. The Allo-OMC group also displayed decreased lymphocyte infiltration into the facial allograft. Both groups showed similar percentages of B cells, T cells, natural killer cells, macrophages, and dendritic cells in the blood, spleen, and lymph nodes. However, a decrease in pro-inflammatory T helper 1 cells and an increase in anti-inflammatory regulatory T cells were observed in the blood and lymph nodes of the Allo-OMC group. Significantly increased percentages of donor immune cells were also observed in three lymphoid organs of the Allo-OMC group, suggesting mixed chimerism induction. These results indicated that the mandible has the potential to induce anti-inflammatory effects and mixed chimerism for prolonging facial allograft survival. The immunomodulatory understanding of the mandible could contribute to reducing the use of immunosuppressive regimens in clinical face allotransplantation including the mandible.

14 December 2025 in Journal of Biophotonics
Verified
Journal Article
Closed access
AAAna Elena Aviña
Ana Elena Aviña
ECEvan Yuan‐Hao Chen
Evan Yuan‐Hao Chen
KCKate Ming‐Yu Chuang
Kate Ming‐Yu Chuang
CCChe‐Yi Chang
Che‐Yi Chang
CCCheng‐Jen Chang
Cheng‐Jen Chang
TYTzu‐Sen Yang
Tzu‐Sen Yang

5 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AAAna Elena Aviña
Ana Elena Aviña
Nguyen Le Thanh HangNguyen Le Thanh Hang
Nguyen Le Thanh Hang
CCChe-Yi Chang
Che-Yi Chang
YCYi-Fan Chen
Yi-Fan Chen
YYYun Yen
Yun Yen
TYTzu-Sen Yang
Tzu-Sen Yang
Age-related muscle decline is associated with impaired mitochondrial bioenergetics, altered redox signaling, and reduced myogenic capacity, yet how photobiomodulation (PBM) source characteristics shape these processes under replicative aging remains unclear. Here, we investigated source-specific PBM responses in C2C12 myoblasts using a 660 nm light-emitting diode (LED) and an 830 nm near-infrared (NIR) laser across fluence ranges and replicative stages. Single-cell screening performed at passage 25 identified 5 J/cm² as the optimal fluence for both sources, producing biphasic increases in mitochondrial membrane potential and ROS. Population-level assays in young (≤5 passages) and old (≥30 passages) cells revealed divergent downstream outcomes. LED irradiation elicited stronger metabolic activation and ATP production, particularly in aged cells, whereas NIR irradiation robustly enhanced myogenic fusion in both age groups and partially rescued differentiation deficits in aged myoblasts. Bulk ROS increased significantly after PBM independent of source, while extracellular vesicle release displayed age-dependent source sensitivity, with NIR favoring canonical small EV populations in young cells and LED inducing greater particle release in aged cells. Together, these findings demonstrate that PBM engages conserved mitochondrial signaling while source-specific delivery and wavelength differentially directs metabolic, paracrine, and myogenic outputs under replicative aging conditions.